Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 5/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 4/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 4/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | BRAF | P15056 | 4/20 | 1.00 |
| ▸ | BCR | P11274 | 4/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 1.00 |
| ▸ | NBAS | A2RRP1 | 2/20 | 1.00 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 1.00 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 1.00 |
| ▸ | AGPS | O00116 | 2/20 | 1.00 |
| ▸ | MYO1F | O00160 | 2/20 | 1.00 |
| ▸ | SNAP23 | O00161 | 2/20 | 1.00 |
| ▸ | AP3B1 | O00203 | 2/20 | 1.00 |
| ▸ | PSMD12 | O00232 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699731 | 1.00 | ABL1 (1.00) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL29380618 | 1.00 | ABL1 (1.00) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL4697866 | 0.94 | BRAF (0.89) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL24532059 | 0.92 | ABL1 (0.86) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL4697696 | 0.92 | BRAF (0.86) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL23092285 | 0.92 | BRAF (0.86) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL29688472 | 0.92 | BRAF (0.86) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL22024695 | 0.92 | BRAF (0.86) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL16136600 | 0.91 | ABL1 (0.84) | ABL1MAPK14DDR1DDR2LCK | |
| SCHEMBL24532058 | 0.91 | ABL1 (0.83) | ABL1MAPK14DDR1DDR2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| WO-2026043541-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TUFTS MEDICAL CENTER, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4636093-A1 | TARGETING MAPK-ERK PATHWAY FOR ENHANCING NUCLEIC ACID DELIVERY | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (DE) | 2025-10-22 | — | — | EP | claimed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | claimed |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | DAY ONE BIOPHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | claimed |
| CN-118806766-A | Application of NVP-BHG712 in preparation of medicines for treating hepatic fibrosis | 贵州医科大学附属医院 | 2024-10-22 | — | — | CN | claimed |
| US-12104168-B2 | Cell culture medium | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2024-10-01 | — | — | US | claimed |
| WO-2024182413-A1 | THERAPEUTIC METHODS | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| US-20220305003-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2022-09-29 | — | — | US | claimed |
| EP-3982977-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | Children's Medical Research Institute (AU) | 2022-04-20 | — | — | EP | claimed |
| CN-114369577-A | Cattle induced expansion pluripotent adult stem cell, line establishing method and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| CN-114369567-A | Method for establishing bovine expanded pluripotent embryonic stem cells and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3964214-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-09 | — | — | EP | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-20220062269-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-03 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | ABL1 751/4885MAPK14 560/4885DDR1 787/4885 |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | BRAF, ARAF, KRAS | ABL1 41/4885MAPK14 1776/4885DDR1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.